Reuters logo
BRIEF-Amgen, Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies
January 9, 2017 / 9:08 AM / in a year

BRIEF-Amgen, Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

Jan 9 (Reuters) - Amgen Inc

* Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies

* Amgen -Immatics will receive upfront fee of $30 million, is eligible to receive over $500 million in development,regulatory and commercial milestone payments

* Amgen -research collaboration,exclusive license agreement to develop next-generation,T-cell engaging bispecific immunotherapies targeting multiple cancers Source text for Eikon: Further company coverage: (Bengaluru Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below